Protara Therapeutics, Inc.

What they do

Protara is a New York City based clinical-stage company developing two programs: TARA-002, an investigational cell therapy based on the immunopotentiator OK-432, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral support. TARA-002 is in development in non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The company holds worldwide rights to TARA-002 excluding Japan and Taiwan, where the related OK-432 is approved for LMs and multiple oncologic indications. Neither product candidate has been approved by the FDA, and the company has not generated any revenues from product sales.

Revenue drivers

• TARA-002 in NMIBC (lead oncology program) — Pre-revenue; the lead program, with the Phase 2 ADVANCED-2 trial enrolling a BCG-Unresponsive cohort of 75 to 100 patients designed to be registrational, and Cohort A having completed enrollment with 31 BCG-Naive or BCG-Exposed CIS patients.
• TARA-002 in lymphatic malformations (LMs) — Pre-revenue; being evaluated in the pivotal Phase 2 STARBORN-1 trial in pediatric patients with macrocystic and mixed cystic LMs, with a BLA submission planned for the second half of 2027.
• IV Choline Chloride for parenteral support patients — Pre-revenue; in the registrational THRIVE-3 trial in patients dependent on long-term parenteral support, with interim results expected in the fourth quarter of 2026.

Recent performance

Protara reported a net loss of $57.4 million for 2025, compared with a net loss of $44.6 million for 2024, while diluted EPS improved to $(1.34) from $(2.17). Operating cash flow was negative $56.4 million for 2025 versus negative $35.8 million for 2024. As of June 30, 2026, the company reported total assets of $176.1 million, total liabilities of $14.8 million, shareholder equity of $161.3 million, and cash and equivalents of $17.1 million, with approximately $161.9 million in unrestricted cash, cash equivalents and marketable debt securities. No revenue from product sales has been recognized.

Strategy

Management's stated priorities are completing enrollment of the BCG-Unresponsive registrational cohort of ADVANCED-2 in the fourth quarter of 2026 and redesigning ADVANCED-3 as a multi-cohort, open-label exploratory trial in broader high-grade, high-risk NMIBC populations. In LMs, the company expects to complete enrollment and provide an update on STARBORN-1 in the fourth quarter of 2026 and to submit a BLA for TARA-002 in the second half of 2027, based on Breakthrough Therapy designation discussions with the FDA. For IV Choline Chloride, enrollment continues in the registrational THRIVE-3 trial, with interim results expected in the fourth quarter of 2026. The company states that it will need to raise additional capital to finance its current strategic plans and ongoing and future clinical trials.

Risks

• No product revenue and no approved products — Neither TARA-002 nor IV Choline Chloride has been approved by the FDA or comparable authorities, and the company has never generated revenue from product sales and does not expect to in the near term.
• Need for additional capital — The company states it will need to raise additional capital to finance current strategic plans, including ongoing and future clinical trials and research and development.
• Accumulated deficit and continuing losses — As of June 30, 2026, accumulated deficit was approximately $341.9 million, and the company expects to continue to incur significant and increasing operating losses for at least the next few years.
• Clinical and regulatory uncertainty — The company has not yet demonstrated an ability to successfully complete registrational clinical trials or complete development or commercialization of any product candidate, and clinical trial timing and outcomes remain uncertain.

Outlook

Management expects to complete enrollment of the BCG-Unresponsive cohort of ADVANCED-2 in the fourth quarter of 2026 and to report interim results from the registrational THRIVE-3 trial of IV Choline Chloride in the fourth quarter of 2026. The company also expects to provide an update and complete enrollment of the STARBORN-1 trial in LMs in the fourth quarter of 2026 and to submit a BLA for TARA-002 in LMs in the second half of 2027. Based on cash, cash equivalents and investments of approximately $162 million as of June 30, 2026, management states the balance is expected to support planned operations into 2028. The company continues to expect to incur significant expenses and increasing operating losses.